Purchase this article with an account.
Maurizio Parodi, Pierluigi Iacono, Ugo Introini, Carlo La Spina, Luigi Berchicci, Anita Leys, Francesco Bandello; Intravitreal Bavacizumab for Non-Subfoveal Choroidale Neovascularization Associated with Angioid Streaks. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3859.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the effects of intravitreal bevacizumab injections in the treatment of non-subfoveal choroidal neovascularization (CNV) associated with angioid streaks (AS). Design: Retrospective study.
Fifteen patients (15 eyes) affected by juxtafoveal or extrafoveal CNV secondary to AS were considered in the study. All patients underwent a complete ophthalmologic examination, including ETDRS best corrected visual acuity (BCVA) measurement, optical coherence tomography (OCT), and fluorescein angiography (FA). The protocol treatment included a first injection, followed by repeated injections over a 12-month follow-up period on the basis of the detection of any type of fluid on OCT and/or presence of leakage on FA Primary outcome measures: Mean changes in BCVA and proportion of eyes gaining at least 10 letters (2 ETDRS lines) at the end of the follow-up. Secondary outcomes: Mean changes of central macular thickness (CMT) and extension to the fovea.
Mean BCVA did not change throughout the follow-up period, being 0.2±0.2 LogMAR at baseline and 0.2±0.3 LogMAR at the 12-month examination. A functional improvement of at least 2 ETDRS lines was achieved by 5 eyes (33%), with 3 eyes (20%) gaining 3 lines. Mean CMT at baseline was 215±13µm and 225±85µm at the 12-month examination. Two eyes (13.3%) showed CNV extension to the fovea.
Intravitreal bevacizumab injection can be regarded as a beneficial approach for the management of non-sbfoveal CNV secondary to AS over a one-year follow-up. Further studies are warranted to confirm our preliminary results.
This PDF is available to Subscribers Only